Remodelling of energy storing white fat into energy expending beige fat could be a promising strategy to reduce adiposity. Here, we show that the bile acid-responsive membrane receptor TGR5 mediates ...beiging of the subcutaneous white adipose tissue (scWAT) under multiple environmental cues including cold exposure and prolonged high-fat diet feeding. Moreover, administration of TGR5-selective bile acid mimetics to thermoneutral housed mice leads to the appearance of beige adipocyte markers and increases mitochondrial content in the scWAT of Tgr5
mice but not in their Tgr5
littermates. This phenotype is recapitulated in vitro in differentiated adipocytes, in which TGR5 activation increases free fatty acid availability through lipolysis, hence fuelling β-oxidation and thermogenic activity. TGR5 signalling also induces mitochondrial fission through the ERK/DRP1 pathway, further improving mitochondrial respiration. Taken together, these data identify TGR5 as a druggable target to promote beiging with potential applications in the management of metabolic disorders.
It has been proposed that diet-induced obesity at thermoneutrality (TN; 29°C) is reduced by a UCP1-dependent thermogenesis; however, it has not been shown how UCP1-dependent thermogenesis can be ...activated in the absence of sympathetic activity. A recent study provides such a mechanism by showing that dietary bile acids (BAs) suppress obesity in mice fed a high-fat diet (HFD) by a mechanism dependent on type 2 deiodinase (DIO2); however, neither a role for UCP1 nor the influence of sympathetic activity was properly assessed. To test whether the effects of BAs on adiposity are independent of Ucp1 and cold-activated thermogenesis, obesity phenotypes were determined in C57BL6/J.(+)/(+) (WT) and C57BL6/J.Ucp1.(-)/(-) mice (Ucp1-KO) housed at TN and fed a HFD with or without 0.5% (wt/wt) cholic acid (CA) for 9 wk. CA in a HFD reduced adiposity and hepatic lipogenesis and improved glucose tolerance in WT but not in Ucp1-KO mice and was accompanied by increases in food intake and energy expenditure (EE). In iBAT, CA increased Ucp1 mRNA and protein levels 1.5- and twofold, respectively, and increased DIO2 and TGR5 protein levels in WT mice. Despite enhanced Dio2 expression in Ucp1-KO and Ucp1-KO-CA treated mice, this did not enhance the ability of BAs to reduce obesity. By comparing the effects of BAs on WT and Ucp1-KO mice at TN, our study showed that BAs suppress diet-induced obesity by increasing EE through a mechanism dependent on Ucp1 expression, which is likely independent of adrenergic signaling.
Evidence from animal studies continues to document the effectiveness of brown fat based thermogenesis in stimulating energy expenditure to reduce obesity. Evidence shows that the number of brown ...adipocytes in white fat is determined by developmental mechanisms, not the environment. The large variability in the capacity for brown fat thermogenesis comes from genetic variability in developmental mechanisms extent in the animal. This genetic variability ultimately drives the capacity for induction of the brown adipocyte phenotype in response to environmental signals in adult animals. We highlight recent studies that suggest a role for gut microbiota in the regulation of brown fat thermogenesis that is based, in part, upon the observation that bile acids can effectively induce thermogenesis by interscapular brown fat at thermoneutrality.
•The number of brown adipocytes is determined during early postnatal development.•The brown adipocyte phenotype in adult white fat is transiently activated upon cold stimulation.•Gut microbiota modulates the brown adipocyte phenotype as a function of ambient temperature.•Bile acids induce the brown adipocyte phenotype in iBAT at thermoneutrality.
Maintenance of body temperature in cold-exposed animals requires induction of thermogenesis and management of fuel. Here, we demonstrated that reducing ambient temperature attenuated diet-induced ...obesity (DIO), which was associated with increased iBAT thermogenesis and a plasma bile acid profile similar to that of germ-free mice. We observed a marked shift in the microbiome composition at the phylum and family levels within 1 day of acute cold exposure and after 4 weeks at 12°C. Gut microbiota was characterized by increased levels of Adlercreutzia, Mogibacteriaceae, Ruminococcaceae, and Desulfovibrio and reduced levels of Bacilli, Erysipelotrichaceae, and the genus rc4-4. These genera have been associated with leanness and obesity, respectively. Germ-free mice fed a high-fat diet at room temperature gained less adiposity and improved glucose tolerance when transplanted with caecal microbiota of mice housed at 12°C compared to mice transplanted with microbiota from 29°C. Thus, a microbiota-liver-BAT axis may mediate protection against obesity at reduced temperature.
Display omitted
•Gut microbiota is altered during suppression of obesity in a cold environment•Cold-adapted microbiota improves host bile acid and energy metabolism•Acute effects of cold-adapted microbiota are linked to thermogenesis in iBAT•Cold-adapted microbiota may signal through FXR and AMPK
Zietak et al. show that the gut microbiota contributes to the beneficial effects of cold on adiposity via a mechanism involving the production of conjugated bile acids and AMPK activation. Transfer of gut microbiota from cold-exposed mice reduces diet-induced obesity in germ-free recipient mice.
Nicotinamide adenine dinucleotide (NAD
) is a co-substrate for several enzymes, including the sirtuin family of NAD
-dependent protein deacylases. Beneficial effects of increased NAD
levels and ...sirtuin activation on mitochondrial homeostasis, organismal metabolism and lifespan have been established across species. Here we show that α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD), the enzyme that limits spontaneous cyclization of α-amino-β-carboxymuconate-ε-semialdehyde in the de novo NAD
synthesis pathway, controls cellular NAD
levels via an evolutionarily conserved mechanism in Caenorhabditis elegans and mouse. Genetic and pharmacological inhibition of ACMSD boosts de novo NAD
synthesis and sirtuin 1 activity, ultimately enhancing mitochondrial function. We also characterize two potent and selective inhibitors of ACMSD. Because expression of ACMSD is largely restricted to kidney and liver, these inhibitors may have therapeutic potential for protection of these tissues from injury. In summary, we identify ACMSD as a key modulator of cellular NAD
levels, sirtuin activity and mitochondrial homeostasis in kidney and liver.
Nicotinamide adenine dinucleotide (NAD.sup.+) is a co-substrate for several enzymes, including the sirtuin family of NAD.sup.+-dependent protein deacylases. Beneficial effects of increased NAD.sup.+ ...levels and sirtuin activation on mitochondrial homeostasis, organismal metabolism and lifespan have been established across species. Here we show that alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase (ACMSD), the enzyme that limits spontaneous cyclization of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde in the de novo NAD.sup.+ synthesis pathway, controls cellular NAD.sup.+ levels via an evolutionarily conserved mechanism in Caenorhabditis elegans and mouse. Genetic and pharmacological inhibition of ACMSD boosts de novo NAD.sup.+ synthesis and sirtuin 1 activity, ultimately enhancing mitochondrial function. We also characterize two potent and selective inhibitors of ACMSD. Because expression of ACMSD is largely restricted to kidney and liver, these inhibitors may have therapeutic potential for protection of these tissues from injury. In summary, we identify ACMSD as a key modulator of cellular NAD.sup.+ levels, sirtuin activity and mitochondrial homeostasis in kidney and liver.
Nicotinamide adenine dinucleotide (NAD+) is a co-substrate for several enzymes, including the sirtuin family of NAD+dependent protein deacylases. Beneficial effects of increased NAD+ levels and ...sirtuin activation on mitochondrial homeostasis, organismal metabolism and lifespan have been established across species. Here we show that a-aminoß-carboxymuconate-s-semialdehyde decarboxylase (ACMSD), the enzyme that limits spontaneous cyclization of a-amino-ß-carboxymuconate-s-semialdehyde in the de novo NAD+ synthesis pathway, controls cellular NAD+ levels via an evolutionarily conserved mechanism in Caenorhabditis elegans and mouse. Genetic and pharmacological inhibition of ACMSD boosts de novo NAD+ synthesis and sirtuin 1 activity, ultimately enhancing mitochondrial function. We also characterize two potent and selective inhibitors of ACMSD. Because expression of ACMSD is largely restricted to kidney and liver, these inhibitors may have therapeutic potential for protection of these tissues from injury. In summary, we identify ACMSD as a key modulator of cellular NAD+ levels, sirtuin activity and mitochondrial homeostasis in kidney and liver.
PDF
